Bjørn Atle Bjørnbeth joins the board
Dr. Bjørn Atle Bjørnbeth joined the board of Oslo Cancer Cluster during the annual general meeting.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 276 entries.
Dr. Bjørn Atle Bjørnbeth joined the board of Oslo Cancer Cluster during the annual general meeting.
Debattinnlegg: Innføring av nye legemidler for små pasientgrupper tar unødvendig lang tid. Noen blir ikke tatt i bruk i Norge i det hele tatt. Det er en utfordring, skriver artikkelforfatterne.
We want to highlight the fruitful collaborations in the cluster. In a new article series, we present members who have a cluster story to tell. This week, we meet LINK Medical.
Novartis joins the IMPRESS oncology study with six of its cancer medicines to treat up to one hundred patients.
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.